Enfermedad meningocócica: epidemiología, diagnóstico y vacunación

Autores/as

  • Marla Groves Pinett Universidad de Ciencias Médicas
  • Arturo Abdelnour Universidad de Ciencias Médicas
  • Carolina Soley Universidad de Ciencias Médicas
  • Adriano Arguedas Mohs Universidad de Ciencias Médicas

DOI:

https://doi.org/10.51481/amc.v55i1.777

Palabras clave:

enfermedad meningocócica, epidemiologia, serogrupos, vacunas

Resumen

"La enfermedad meningocócica invasiva causada por N. meningitidis es un problema global de salud pública, por su alta morbilidad y mortalidad. Esta patología es causada en su mayoría por los serogrupos A, B, C, W-135 e Y. La prevención mediante la vacunación es la mejor herramienta para disminuir la carga mundial de esta enfermedad. Las vacunas no conjugadas que toman como base solo el polisacárido externo, aun cuando son beneficiosas en epidemias, producen pobre inmunogenicidad a largo plazo en los niños menores de dos años de edad, que representan la población de mayor riesgo. Las vacunas de nueva generación, en donde el polisacárido es conjugado con proteínas transportadoras, producen respuesta inmune en niños menores de 2 años, lo cual podría producir una reducción importante de la enfermedad en esta población de alto riesgo..."

Citas

Perrett K, Snape M, Ford K, John T, Yu L, Langley M, et al. Immunogenicity and Immune Memory of a NonadjuvantedQuadrivalent Meningococcal Glycoconjugate Vaccine in Infants. Pediatr Infect Dis J; 2009; 28: 186-193

The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease: Conference report, 2011; 29: 3363-3671. En: http://www.elsevier.com/ locate/vaccine)

Pace D, Pollard A. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines. Arch. Dis. Child. 2007; 92: 909-915

Halperina S, Bettingerb J, Greenwood B, Harrisond L, Jelfse J, Ladhanif S, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2011; 695 : 1–10

Yogev R, Tan T. Meningococcal disease: The advances and challenges in meningococcal disease prevention. Human Vaccines 2011; 7: 828-837

Stephens D, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis Lancet 2007; 369: 2196–210

Rennels M, King J, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J; 2004; 23: 429-35

Fijen C, Bredius R, Kuijper E, Out T, De Haas M, de Wit A et al. The role of Fc gamma receptor polymorphisms and C3 in the immune defense against Neisseria meningitidis in complementdeficient individuals. ClinExpImmunol. 2000; 120: 338–45.

Hibberd M, Sumiya M, Summerfield J, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999; 353: 1049–53.

Rosenstein M, Perkins B, Stephens D, Popovic T, Hughes J, Popovic A. Meningococcal disease. N Engl J Med 2001; 34: 1378-1388

Apicella M. Mandell G, Bennett J, Dolin R. Principles and Practice of Infectious Disease 6th edition Philadelphia: Elsevier Churchill Livingstone Publishers, 2005: 2498-513.

Ramsay M, Fox A. Invasive Neisseria meningitidis In Europe 2006. London: Health Protection Agency. 53 paginas, recuperado el 8 de noviembre 2010, http://www.euibis. org/documents/2006 meningo.pdf

Parkhill J, Achtman M, James KD, et al. Complete DNA sequence of a serogroup A strain of Neisseria meningtidis. Nature. 2000; 404: 502-06

Frosch M, Weisgerber C, Meyer TF. Molecular characterization and expresión in E. Coli of the gene complex encoding the polysaccharide capsule of Neisseria meningtidis Group B. ProcNatlAcad and Sci USA 1989; 86: 1669-73.

Sexton K, Lennon D, Oster P, Crengle S, Martin D, Mulholland K, et al. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. NZMJ, 2004, 117: 200.

Greeff S, de Melker H, Spanjaard L, Schouls L, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006; 25: 79–80.

Palazzi-Safadi M, Leitre O. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. NeurologicResearch 2010; 32: 263-271.

Pérez A, Molina I, García M. Comportamiento de la enfermedad meningocócica en el territorio de Ciudad de La Habana antes y después de la vacunación. Rev Cubana MedTrop. 2002; 54

Organización Panamericana de la Salud. Informe Regional de SIREVA II, 2010: datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcuspneumoniae, Haemophilusinfluenzae y Neisseria meningitidisen procesos invasores. Washington, D.C.: 2010. En: http://new.paho.org/ hq/index.php

Ragunathan L, Ramsay M, Borrow R, Guiver M, Gray S,

Kaczmarski E. Clinical Features, Laboratory Findings and Management of Meningococcal Meningitis in England and Whales: Report of a 1997 Survey. Journal of Infection 2000; 40: 74-79

Almeida L, Franco-Paredes C, Pérez L, Santos-Preciado J. Enfermedad por meningococo, Neisseria meningitidis: perspectiva epidemiológica, clínica y preventiva. Salud pública Méx 2004; 46, 5.

Witherow F, Rudd P. Latex agglutination testing in bacterial meningitis, Arch Dis Child J, 1995; 73: 160-161

Sacchi C, Fukasawa L, Goncalves M, Salgado M, Shutt K, Carvalhanas T et al. Incorporation of RT-PCR into Routine Public Health Surveillance for Culture Negative Bacterial Meningococcal Meningitis in Sao Paulo State, Brazil. Infectious Diseases. 201, PLoS one 6.

Van Gastel E, Bruynseels P, Verstrepen W, Mertens A. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of pneumococcal and meningococcal meningitis in a tertiary care hospital. Eur J ClinMicrobiol Infect Dis 2007 26:651–653

Rebelo M, Boente R, Matos J, Hofer C, Barroso D. Assessment of a two-step nucleic acid amplification assay for detection of Neisseria meningitidis followed by capsular genogrouping. MemInst Oswaldo Cruz. 2006; 101; 7: 809-813

Goldschneider I, Gotschlich E, Artenstein M. Human immunity to the meningococcus. Development of natural immunity. J Exp Med 1969; 129: 1327-48

Brynjolfsson S, Henneken M, Bjarnarson S, Mori E, Del Giudice G, Jonsdottir I. Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. J Infect Dis. 2012; 205: 422-30.

Pollard A, Perrett K, Beverley P. Maintaining protection against invasive bacteria with protein– polysaccharide conjugate vaccines. Immunology 2009; 213-220.

US Food and Drug Administration. Resumen de bases para acciones regulatorias de Menactra. 2011. En http:// www.fda. gov/BiologicsBloodVaccines/Vaccines

US Food and Drug Administration [Internet]. Resumen de bases para acciones regulatorias de Menveo. 2011. En:http://www. fda.gov/BiologicsBloodVaccines/Vaccines

Priscilla Velentgas. Guillain-Barré Syndrome (GBS) After Receipt of Menactra®. Advisory Committee on Immunization Practices (ACIP) Summary Report June 23-24, 2010. En http://www.cdc.

gov/vaccines/recs/acip/downloads/min-jun10.txt

Centers for Disease Control [Internet]. Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 2005; 54: 1–21.

US Food and Drug Administration [Internet]. MENVEO® [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection. 2010. En: www.fda.gov/BiologicsBloodVaccines/ Vaccines

Arguedas A, Soley C, Loaizaa C, Rincona G, Guevaraa S, Pereza A et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010; 28: 3171–3179

Snape M, Perrett K, Ford K, John T, Pace D, Yu L et al. Immunogenicityof a tetravalent meningococcal glycoconjugatevaccineininfants: a randomized controlled trial. JAMA; 2008; 299: 173-84

Richmond P, Borrow R. Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunological memory after a single dose in UK toddlers. J Infect Dis. 2001; 183: 160-3.

Richmond P, Borrow R, Goldblatt D, Southern J, Ashton L, Andrews N, et al. Immunogenicity of, and immunological memory to, a reduced primary Schedule of meningococcal C-tetanus toxoide conjugate vaccine in infants in the United Kingdom. Infect Immun. 2003; 71: 55549-55

Palazzi-Safadi M, Pimentel-Barros A. Meningococcal conjugate vaccines: efficacy and new combinations. J Pediatria 2006; 35-44

Bjune G, Høiby E, Grønnesby J, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338: 1093-6

Vesikari T, et al. Immunogenicity of an Investigational Multicomponent Meningococcal Serogroup B Vaccine in Healthy Infants at 2, 4 and 6 months of Age. 2010. En: http://www. landesbioscience.com/journals/vaccines

Kelly C, Arnold R, Galloway Y, O’Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007; 166: 817–23

New Zealand Ministry of Health. Immunisation: meningococcal B (MeNZBTM). 2010. En: http://www.moh.govt.nz/moh.nsf/ indexmh/immunisation-diseasesandvaccines menzb#start

Harrison L, Trotter C, Ramsay M. Global epidemiology of meningococcal disease. Vaccine 2009; 27: 51–63.

Harrison L, Jolley K, Shutt K. Antigenic shift and increased incidence of meningococcal disease. J Infect Disease 2006; 193: 1266–74

New Zealand Ministry of Health. Meningococcal disease in New Zealand. En: http://www.moh.govt. nz/meningococcal

ESR (Institute of Environmental Science and Research Limited). The epidemiology of meningococcal disease in New Zealand in 2007. En: http://www.surv.esr.cri.nz/PDF_surveillance/ MeningococcalDisease/2008/20 08AnnualRpt.pdf.

Palazzi-Safadi M, Pimentel-Barros A. Meningococcal conjugate vaccines: efficacy and new combinations. J Pediatria 2006; 35-44

Descargas

Publicado

2013-04-05 — Actualizado el 2013-01-01

Versiones

Cómo citar

Groves Pinett, M., Abdelnour, A., Soley, C., & Arguedas Mohs, A. (2013). Enfermedad meningocócica: epidemiología, diagnóstico y vacunación. Acta Médica Costarricense , 55(1), 8-17. https://doi.org/10.51481/amc.v55i1.777 (Original work published 5 de abril de 2013)